- Home
- PRPL vs KPTI Comparison
PRPL vs KPTI Comparison
Compare PRPL & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPL
- KPTI
- Stock Information
- Founded
- PRPL 2010
- KPTI 2008
- Country
- PRPL United States
- KPTI United States
- Employees
- PRPL N/A
- KPTI N/A
- Industry
- PRPL Home Furnishings
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- PRPL Consumer Discretionary
- KPTI Health Care
- Exchange
- PRPL Nasdaq
- KPTI Nasdaq
- Market Cap
- PRPL 96.8M
- KPTI 44.5M
- IPO Year
- PRPL N/A
- KPTI 2013
- Fundamental
- Price
- PRPL $0.73
- KPTI $4.31
- Analyst Decision
- PRPL Hold
- KPTI Buy
- Analyst Count
- PRPL 2
- KPTI 6
- Target Price
- PRPL $1.25
- KPTI $48.50
- AVG Volume (30 Days)
- PRPL 666.3K
- KPTI 59.0K
- Earning Date
- PRPL 08-04-2025
- KPTI 08-05-2025
- Dividend Yield
- PRPL N/A
- KPTI N/A
- EPS Growth
- PRPL N/A
- KPTI N/A
- EPS
- PRPL N/A
- KPTI N/A
- Revenue
- PRPL $472,015,000.00
- KPTI $142,126,000.00
- Revenue This Year
- PRPL N/A
- KPTI $2.09
- Revenue Next Year
- PRPL $10.65
- KPTI $12.90
- P/E Ratio
- PRPL N/A
- KPTI N/A
- Revenue Growth
- PRPL N/A
- KPTI 1.19
- 52 Week Low
- PRPL $0.56
- KPTI $3.51
- 52 Week High
- PRPL $1.50
- KPTI $16.95
- Technical
- Relative Strength Index (RSI)
- PRPL 48.69
- KPTI 42.77
- Support Level
- PRPL $0.70
- KPTI $4.12
- Resistance Level
- PRPL $0.82
- KPTI $4.64
- Average True Range (ATR)
- PRPL 0.05
- KPTI 0.29
- MACD
- PRPL -0.00
- KPTI 0.04
- Stochastic Oscillator
- PRPL 45.34
- KPTI 34.80
About PRPL Purple Innovation Inc.
Purple Innovation Inc is a comfort innovation company. The company designs, manufactures and sells a range of comfort technology offerings, including mattresses, a pillow, cushions, sheets, bed platforms, and other products. It sells its products through online channels, traditional wholesale partners and third-party online retailers.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.